Xmt-2056
HER2-positive Non-Small Cell Lung Cancer
Day One Biopharmaceuticals, Inc.Phase 1
—
Rating in progress
Xmt-2056 in HER2-positive Non-Small Cell Lung Cancer is in the Floatz rating universe. The engine has not yet published a v0.2 rating for this asset. This page will update automatically once scoring completes.
Methodology v0.2 · Active